دورية أكاديمية
أعرض في EDS

Postnatal corticosteroid therapy in bronchopulmonary dysplasia - why animal studies disagree with clinical trials?

التفاصيل البيبلوغرافية
العنوان: Postnatal corticosteroid therapy in bronchopulmonary dysplasia - why animal studies disagree with clinical trials?
المؤلفون: Harijith A; Department of Pediatrics, Case Western Reserve University, 2109, Adelbert Road, Cleveland, OH, 44106, USA. axh775@case.edu., Raffay TM; Department of Pediatrics, Case Western Reserve University, 2109, Adelbert Road, Cleveland, OH, 44106, USA., Ryan RM; Department of Pediatrics, Case Western Reserve University, 2109, Adelbert Road, Cleveland, OH, 44106, USA.
المصدر: Pediatric research [Pediatr Res] 2024 Jun 24. Date of Electronic Publication: 2024 Jun 24.
Publication Model: Ahead of Print
نوع المنشور: Journal Article; Comment
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 0100714 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1530-0447 (Electronic) Linking ISSN: 00313998 NLM ISO Abbreviation: Pediatr Res Subsets: MEDLINE
أسماء مطبوعة: Publication: 2012- : New York : Nature Publishing Group
Original Publication: Basel ; New York : Karger.
مستخلص: The systematic review and meta-analysis of newborn animal models by Irene Lok et al. is the first to extensively summarize the literature regarding postnatal systemic corticosteroid use on lung development of newborn rodent models. The meta-analysis showed that the use of postnatal corticosteroids resulted in a reduction in body weight along with persistent alveolar simplification. The most frequently used corticosteroid was dexamethasone. Corticosteroids have been extensively used in clinical trials in preterm newborns. Trials using early systemic administration of corticosteroids reduced the rate of BPD or mortality with no increase in the rates of cerebral palsy. Use of late systemic corticosteroids (administered >7 days after birth) also reduced the rate of BPD, mortality, and combined outcome of mortality or BPD. Late systemic corticosteroids showed no impact on the rates of neurodevelopmental outcomes in later childhood. It is important to note that later stages of inflammation leading to a more severe form of BPD continues to be a problem with no clear therapy in sight. The authors made a critical point in their paper - the negative effects of steroids were greater in the normal lung control animals than in the injured. This conveys caution in using steroids in a prophylactic manner. IMPACT: Use of systemic corticosteroids in clinical trials have shown good response in preterm neonates evidenced by reduced rate of bronchopulmonary dysplasia. Rodent models have not shown a similar beneficial response. Use of systemic corticosteroids have caused greater arrest of lung development in rodent models with normal lungs compared to those with lung damage.
(© 2024. The Author(s).)
التعليقات: Comment on: Pediatr Res. 2024 Mar 16. doi: 10.1038/s41390-024-03114-6. (PMID: 38493255)
References: Cummings, J. & Pramanik, A. K. Committee On Fetus And Newborn Postnatal corticosteroids to prevent or treat chronic lung disease following preterm birth. Pediatrics 149, e2022057530 (2022). (PMID: 10.1542/peds.2022-05753037917016)
Yoder, B. A., Harrison, M. & Clark, R. H. Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics 124, 673–679 (2009). (PMID: 10.1542/peds.2008-279319620192)
Doyle, L. W. Victorian Infant Collaborative Study Group et al. Ventilation in extremely preterm infants and respiratory function at 8 years. N. Engl. J. Med. 377, 329–337 (2017). (PMID: 10.1056/NEJMoa170082728745986)
Balany, J. & Bhandari, V. Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia. Front. Med. 2, 90 (2015). (PMID: 10.3389/fmed.2015.00090)
Baden, M. et al. A controlled trial of hydrocortisone therapy in infants with respiratory distress syndrome. Pediatrics 50, 526–534 (1972). (PMID: 10.1542/peds.50.4.5264561296)
Avery, G. B., Fletcher, A. B., Kaplan, M. & Brudno, D. S. Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics 75, 106–111 (1985). (PMID: 10.1542/peds.75.1.1063880879)
Doyle, L. W. Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Neonatology 118, 244–251 (2021). (PMID: 10.1159/00051595033975319)
Lok I. M. et al. Effects of postnatal corticosteroids on lung development in newborn animals. A systematic review. Pediatr. Res. https://doi.org/10.1038/s41390-024-03114-6 .
Berger, J. & Bhandari, V. Animal models of bronchopulmonary dysplasia. The term mouse models. Am. J. Physiol. Lung Cell Mol. Physiol. 307, L936–L947 (2014). (PMID: 10.1152/ajplung.00159.2014253052494269689)
Hoshikawa, Y. et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol. Genom. 12, 209–219 (2003). (PMID: 10.1152/physiolgenomics.00081.2001)
Irvin, C. G. & Bates, J. H. Measuring the lung function in the mouse: the challenge of size. Respir. Res. 4, 4 (2003). (PMID: 10.1186/rr19912783622184039)
Doyle, L. W., Cheong, J. L., Hay, S., Manley, B. J. & Halliday, H. L. Late (>/= 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst. Rev. 11, CD001145 (2021). (PMID: 34758507)
Baud, O., Alberti, C., Mohamed, D. & Watterberg, K. Low-dose hydrocortisone in extremely preterm infants - Authors’ reply. Lancet 388, 1158–1159 (2016). (PMID: 10.1016/S0140-6736(16)31611-727650090)
Baud, O. et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet 387, 1827–1836 (2016). (PMID: 10.1016/S0140-6736(16)00202-626916176)
Baud, O. et al. Association between early low-dose hydrocortisone therapy in extremely preterm neonates and neurodevelopmental outcomes at 2 years of age. JAMA 317, 1329–1337 (2017). (PMID: 10.1001/jama.2017.269228384828)
Onland, W. et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA 321, 354–363 (2019). (PMID: 10.1001/jama.2018.21443306943226439762)
Watterberg, K. L. et al. Hydrocortisone to improve survival without bronchopulmonary dysplasia. N. Engl. J. Med. 386, 1121–1131 (2022). (PMID: 10.1056/NEJMoa2114897353206439107291)
Richa Lakhotia S. A. B., Zackula R., Raghuveer T. S. Systemic steroids to prevent bronchopulmonary dysplasia in preterm infants: a systematic review, including long-term follow-up, and meta-regression https://2023.pas-meeting.org/fsPopup.asp?Mode=presInfo&PresentationID=1213196 (2023).
تواريخ الأحداث: Date Created: 20240624 Latest Revision: 20240624
رمز التحديث: 20240625
DOI: 10.1038/s41390-024-03361-7
PMID: 38914764
قاعدة البيانات: MEDLINE
الوصف
تدمد:1530-0447
DOI:10.1038/s41390-024-03361-7